Trial Profile
Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC (TORG1426)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 10 Sep 2019 Status changed from active, no longer recruiting to discontinued due to slow accrual, according to the results presented at the 20th World Conference on Lung Cancer.
- 24 Oct 2018 Status changed from recruiting to active, no longer recruiting.